Literature DB >> 1452399

Anticomplementary activity of boswellic acids--an inhibitor of C3-convertase of the classical complement pathway.

A Kapil1, N Moza.   

Abstract

Boswellic acids (BA), an anti-inflammatory and anti-arthritic principle/s of Boswellia serrata, were found to possess anticomplementary activity. It inhibits the in vitro immunohaemolysis of antibody-coated sheep erythrocytes by pooled guinea-pig serum. The reduced immunohaemolysis was found to be due to inhibition of C3-convertase of the classical complement pathway. The threshold concentration for inhibiting C3-convertase was found to be 100 micrograms. However, higher concentrations of BA showed constant inhibitory effects on immunohaemolysis. BA also exhibited weak inhibitory effects on individual components of the complement system. In vivo administration of BA also showed the inhibitory effect on guinea-pig serum.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1452399     DOI: 10.1016/0192-0561(92)90048-p

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  5 in total

1.  Boswellic acids extract attenuates pulmonary fibrosis induced by bleomycin and oxidative stress from gamma irradiation in rats.

Authors:  Eman Noaman Ali; Somaya Zakaria Mansour
Journal:  Chin Med       Date:  2011-09-30       Impact factor: 5.455

2.  What does complement do in Alzheimer's disease? Old molecules with new insights.

Authors:  Yong Shen; Libang Yang; Rena Li
Journal:  Transl Neurodegener       Date:  2013-10-12       Impact factor: 8.014

Review 3.  Review of Anti-Inflammatory Herbal Medicines.

Authors:  Mona Ghasemian; Sina Owlia; Mohammad Bagher Owlia
Journal:  Adv Pharmacol Sci       Date:  2016-05-10

Review 4.  Immunomodulatory properties of triterpenes.

Authors:  Gülin Renda; İçim Gökkaya; Didem Şöhretoğlu
Journal:  Phytochem Rev       Date:  2021-11-18       Impact factor: 7.741

Review 5.  Targeting complement cascade: an alternative strategy for COVID-19.

Authors:  Sureshbabu Ram Kumar Pandian; Sankarganesh Arunachalam; Venkataraman Deepak; Selvaraj Kunjiappan; Krishnan Sundar
Journal:  3 Biotech       Date:  2020-10-19       Impact factor: 2.406

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.